ArticleJACS Au2026
Metastable Protein-Protein Interactions as a Design Principle for PROTACs: Insights from the RIPK1-VHL System.
Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Proteolysis-Targeting Chimeras (PROTACs) eliminate disease-relevant proteins by stabilizing short-lived, metastable protein-protein interactions (PPIs) between a target protein and an E3 ligase. These transient encounter complexes are central to PROTAC activity, yet they are difficult to predict and are often invisible to structure-based or AI-only modeling approaches that favor stable, native interactions. Here, we show that explicitly accounting for metastable PPIs provides an effective design principle for rational PROTAC development. Using large-scale molecular dynamics (MD) simulations combined with integrative generalized master equation (IGME) modeling, we mapped the ensemble of metastable PPIs between receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and the von Hippel-Lindau (VHL) E3 ligase, and identified four distinct PPIs suitable for degrader engagement. We find that different PPIs preferentially accommodate different linker architectures, providing a mechanistic explanation for the counterintuitive experimental observation that PROTACs with very short and very long linkers can consistently yield potent degradation. Guided by this insight, we established a virtual screening workflow for linker design and identified the benzylic position on the VHL ligand as a viable linkage site. Rationally designed novel PROTACs featuring this site achieve complete degradation with subnanomolar to low-nanomolar potency. Our results demonstrate that incorporating protein dynamics into degrader design substantially expands the accessible PROTAC design space.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.